Monoclonal Antibodies (mAbs) Market Analysis By Source (Chimeric, Murine, Humanized, Human), By Type of Production, By Indication (Cancer, Autoimmune, Inflammatory, Infectious, Microbial, Viral Diseases), By End-use (Hospitals, Research, Academic Institutes, Clinics, Diagnostic Laboratories) And Segment Forecasts, 2013 - 2024

Published: Nov, 2016 | Pages: 115 | Publisher: Grand View Research
Industry: Biotechnology | Report Format: Electronic (PDF)

The global monoclonal antibodies (mAbs) market was valued at USD 85.4 billion in 2015 and is expected to reach a value of USD 138.6 billion by 2024. Increasing R&D pertaining to the development of therapeutic mAbs coupled with supportive government initiatives is expected to drive the monoclonal antibodies market growth over the forecast period.

Increasing demand for personalized medicine is a vital factor responsible for the increasing development of therapeutic antibodies to provide targeted therapies as every individual responds in a different manner to a particular treatment. Moreover, related benefits of using mAbs for therapeutic purposes, including fewer adverse effects, homogeneity, specificity, and large-scale production, are contributing toward significant market growth.

In addition, the government initiatives to enable cost-effective production of mAbs is anticipated to propel the emergence of this sector over the forecast period. For instance, the biomanufacturing initiative byNational Institute of Standards and Technology in the U.S. provides scientifically sound regulatory guidelines to ensure effective and safe manufacturing of protein therapeutics and to support biopharmaceutical manufacturers in offering low-cost and high-quality protein drugs across the globe.

Further Key Findings From the Study Suggest:

Human-based mAbs segment is predicted to grow at a lucrative CAGR in the coming years due to their associated benefits and numerous R&D activities conducted for further development of human mAbs. Large number of mAbs of human origin are in phase III clinical trial for cancer treatment

In vitro production of mAbs is anticipated to show the fastest growth owing to its wide-scale adoption by biologics manufacturers due to its greater efficiency in cost and time

The research institute segment is anticipated to exhibit profitable growth due to increasing R&D efforts in the biotech industry as monoclonal antibodies have emerged as a major class of therapeutics for several human diseases, particularly immunological infectious diseases and cancer

The Asia pacific region has significant growth potential due to rising government initiatives in this region supporting the use of mAbs for research and treatment purposes coupled with the surge in sponsored R&D projects for the development of cost-effective therapeutic mAbs.

For instance, government-led fund providers, such as National Natural Science Foundation and National Basic Research Program of China, offer financial support to enterprises and universities to conduct mAb research and development.

The key players serving the monoclonal antibodies market arePfizer, Inc., GlaxoSmithKline plc, Novartis AG, Merck & Co., Inc, Amgen, Inc., Abbott Laboratories, AstraZeneca, Eli Lilly and Company, Mylan N.V., Daiichi Sankyo Company, Ltd., Bayer AG, Bristol Myers Squibb Co.,Johnson & Johnson Services, Inc., Biogen Inc., Thermo Fisher Scientific, Inc., Sanofi Genzyme, F. Hoffmann-La Roche Ltd., and Novo Nordisk A/S.

The introduction of advanced methods for mAb production further encourages the pharmaceutical companies to build their own product pipeline. According to a study published by NCBI at the end of 2013, approximately 816 companies were involved in therapeutic protein research.

 Table of Contents

Chapter 1 Research Methodology & Scope
                    1.1 Region Wise Market Calculation
                       1.1.1 Region Wise Market: Base Estimates
                       1.1.2 Global Market: CAGR Calculation
                    1.2 Region based segment share calculation
                    1.3 List of Secondary Sources

Chapter 2 Executive Summary

Chapter 3 Market Snapshot

Chapter 4 Market Variables, Trends & Scope
                    4.1 Market segmentation & scope
                       4.1.1 Market Driver Analysis
                             4.1.1.1 Increasing incidences of chronic diseases
                             4.1.1.2 Technological advancements
                             4.1.1.3 Growing awareness levels
                    4.2 Market Restraint Analysis
                             4.2.1.1 High cost of therapeutic mAbs
                    4.3 Penetration & growth prospect mapping
                    4.4 Monoclonal Antibodies - SWOT Analysis, By Factor (political & legal, economic and technological)
                    4.5 Industry Analysis - Porter's

Chapter 5 Market Categorization 1: Source Type Estimates & Trend Analysis
                    5.1 Monoclonal antibodies market: Source type movement analysis
                    5.2 Murine
                       5.2.1 Murine market, 2013 - 2024 (USD Billion)
                    5.3 Chimeric
                       5.3.1 Chimeric market, 2013 - 2024 (USD Billion)
                    5.4 Humanized
                       5.4.1 Humanized market, 2013 - 2024 (USD Billion)
                    5.5 Human
                             5.5.1.1 Human market, 2013 - 2024 (USD Billion)

Chapter 6 Market Categorization 2: Production Type Estimates & Trend Analysis
                    6.1 Monoclonal antibodies market: Production type movement analysis
                    6.2 In vitro
                       6.2.1 In vitro market, 2013 - 2024 (USD Billion)
                    6.3 In vivo
                       6.3.1 In vivo market, 2013 - 2024 (USD Billion)

Chapter 7 Market Categorization 3: Indication Estimates & Trend Analysis
                    7.1 Monoclonal antibodies market: Disease movement analysis
                    7.2 Cancer
                       7.2.1 Cancer Market, 2013 - 2024 (USD Billion)
                    7.3 Autoimmune diseases
                       7.3.1 Autoimmune diseases market, 2013 - 2024 (USD Billion)
                    7.4 Inflammatory diseases
                       7.4.1 Inflammatory diseases market, 2013 - 2024 (USD Billion)
                    7.5 Infectious diseases
                       7.5.1 Infectious diseases market, 2013 - 2024 (USD Billion)
                    7.6 Microbial diseases
                       7.6.1 Microbial diseases market, 2013 - 2024 (USD Billion)
                    7.7 Others
                       7.7.1 Others diseases market, 2013 - 2024 (USD Billion)

Chapter 8 Market Categorization 4: End-Use Estimates & Trend Analysis
                    8.1 Monoclonal antibodies market: End-use movement analysis
                    8.2 Hospitals
                       8.2.1 Hospitals market, 2013 - 2024 (USD Billion)
                    8.3 Research Institutes
                       8.3.1 Research institutes market, 2013 - 2024 (USD Billion)
                    8.4 Others
                       8.4.1 Others market, 2013 - 2024 (USD Billion)

Chapter 9 Market Categorization 5: Regional Estimates & Trend Analysis, by Source Type, Production Type, Indication & End-Use
                    9.1 Monoclonal antibodies market shares by region, 2015 & 2024
                    9.2 North America
                       9.2.1 North America Monoclonal antibodies market estimates and forecasts, 2013 - 2024
                       9.2.2 U.S.
                             9.2.2.1 U.S. monoclonal antibodies market estimates and forecasts, 2013 - 2024
                       9.2.3 Canada
                             9.2.3.1 Canada monoclonal antibodies market estimates and forecasts, 2013 - 2024
                    9.3 Europe
                             9.3.1.1 Europe monoclonal antibodies market estimates and forecasts, 2013 - 2024
                       9.3.2 Germany
                             9.3.2.1 Germany monoclonal antibodies market estimates and forecasts, 2013 - 2024
                       9.3.3 UK
                             9.3.3.1 UK monoclonal antibodies market estimates and forecasts, 2013 - 2024
                    9.4 Asia Pacific
                             9.4.1.1 Asia Pacific monoclonal antibodies market estimates and forecasts, 2013 - 2024
                       9.4.2 Japan
                             9.4.2.1 Japan monoclonal antibodies market estimates and forecasts, 2013 - 2024
                       9.4.3 China
                             9.4.3.1 China monoclonal antibodies market estimates and forecasts, 2013 - 2024
                       9.4.4 India
                             9.4.4.1 India monoclonal antibodies market estimates and forecasts, 2013 - 2024
                    9.5 Latin America
                             9.5.1.1 Latin America monoclonal antibodies market estimates and forecasts, 2013 - 2024
                       9.5.2 Brazil
                             9.5.2.1 Brazil monoclonal antibodies market estimates and forecasts, 2013 - 2024
                       9.5.3 Mexico
                             9.5.3.1 Mexico monoclonal antibodies market estimates and forecasts, 2013 - 2024
                    9.6 MEA
                             9.6.1.1 MEA monoclonal antibodies market estimates and forecasts, 2013 - 2024
                       9.6.2 South Africa
                             9.6.2.1 South Africa Monoclonal antibodies market estimates and forecasts, 2013 - 2024

Chapter 10 Competitive Landscape
                    10.1 Strategy framework
                    10.2 Market participation categorization
                    10.3 Company Profiles
                       10.3.1 Novartis International
                             10.3.1.1 Company Overview
                             10.3.1.2 Financial Performance
                             10.3.1.3 Product Benchmarking
                             10.3.1.4 Strategic Initiatives
                       10.3.2 Pfizer
                             10.3.2.1 Company Overview
                             10.3.2.2 Financial Performance
                             10.3.2.3 Product Benchmarking
                             10.3.2.4 Strategic Initiatives
                       10.3.3 GlaxoSmithKline Plc
                             10.3.3.1 Company Overview
                             10.3.3.2 Financial Performance
                             10.3.3.3 Product Benchmarking
                             10.3.3.4 Strategic Initiatives
                       10.3.4 Amgen Inc.
                             10.3.4.1 Company Overview
                             10.3.4.2 Financial Performance
                             10.3.4.3 Product Benchmarking
                             10.3.4.4 Strategic Initiatives
                       10.3.5 Merck & Co., Inc.
                             10.3.5.1 Company Overview
                             10.3.5.2 Financial Performance
                             10.3.5.3 Product Benchmarking
                             10.3.5.4 Strategic Initiatives
                       10.3.6 Daiichi Sankyo
                             10.3.6.1 Company Overview
                             10.3.6.2 Financial Performance
                             10.3.6.3 Product Benchmarking
                             10.3.6.4 Strategic Initiatives
                       10.3.7 Abbott Laboratories
                             10.3.7.1 Company Overview
                             10.3.7.2 Financial Performance
                             10.3.7.3 Product Benchmarking
                             10.3.7.4 Strategic Initiatives
                       10.3.8 AstraZeneca plc
                             10.3.8.1 Company Overview
                             10.3.8.2 Financial Performance
                             10.3.8.3 Product Benchmarking
                             10.3.8.4 Strategic Initiatives
                       10.3.9 Eli Lilly
                             10.3.9.1 Company Overview
                             10.3.9.2 Financial Performance
                             10.3.9.3 Product Benchmarking
                             10.3.9.4 Strategic Initiatives
                       10.3.10 Johnson & Johnson
                             10.3.10.1 Company Overview
                             10.3.10.2 Financial Performance
                             10.3.10.3 Product Benchmarking
                             10.3.10.4 Strategic Initiatives
                       10.3.11 Bayer AG
                             10.3.11.1 Company Overview
                             10.3.11.2 Financial Performance
                             10.3.11.3 Product Benchmarking
                             10.3.11.4 Strategic Initiatives
                       10.3.12 Bristol Myers Squibb
                             10.3.12.1 Company Overview
                             10.3.12.2 Financial Performance
                             10.3.12.3 Product Benchmarking
                             10.3.12.4 Strategic Initiatives
                       10.3.13 F.Hoffman-La Roche Ltd.
                             10.3.13.1 Company Overview
                             10.3.13.2 Financial Performance
                             10.3.13.3 Product Benchmarking
                             10.3.13.4 Strategic Initiatives
                       10.3.14 Mylan N.V.
                             10.3.14.1 Company Overview
                             10.3.14.2 Financial Performance
                             10.3.14.3 Product Benchmarking
                             10.3.14.4 Strategic Initiatives
                       10.3.15 Biogen Idec Inc.
                             10.3.15.1 Company Overview
                             10.3.15.2 Financial Performance
                             10.3.15.3 Product Benchmarking
                             10.3.15.4 Strategic Initiatives
                       10.3.16 Thermo Fisher Scientific
                             10.3.16.1 Company Overview
                             10.3.16.2 Financial Performance
                             10.3.16.3 Product Benchmarking
                             10.3.16.4 Strategic Initiatives
                       10.3.17 Novo Nordisk
                             10.3.17.1 Company Overview
                             10.3.17.2 Financial Performance
                             10.3.17.3 Product Benchmarking
                             10.3.17.4 Strategic Initiatives
                       10.3.18 Sanofi
                             10.3.18.1 Company Overview
                             10.3.18.2 Financial Performance
                             10.3.18.3 Product Benchmarking
                             10.3.18.4 Strategic Initiatives
                       10.3.19 Genzyme
                             10.3.19.1 Company Overview
                             10.3.19.2 Financial Performance
                             10.3.19.3 Product Benchmarking
                             10.3.19.4 Strategic Initiatives

List of Tables

TABLE 1 Country share estimation
TABLE 2 North America monoclonal antibodies market, by source type , 2013 - 2024 (USD Billion)
TABLE 3 North America monoclonal antibodies market, by production type, 2013 - 2024 (USD Billion)
TABLE 4 North America monoclonal antibodies market, by indication, 2013 - 2024 (USD Billion)
TABLE 5 North America monoclonal antibodies market, by end-use, 2013 - 2024 (USD Billion)
TABLE 6 U.S. monoclonal antibodies market, by source type, 2013 - 2024 (USD billion)
TABLE 7 U.S. monoclonal antibodies market, by production type, 2013 - 2024 (USD Billion)
TABLE 8 U.S. monoclonal antibodies market, by indication, 2013 - 2024 (USD Billion)
TABLE 9 U.S. monoclonal antibodies market, by end-use, 2013 - 2024 (USD Billion)
TABLE 10 Canada monoclonal antibodies market, by source type, 2013 - 2024 (USD Billion)
TABLE 11 Canada monoclonal antibodies market, by production type, 2013 - 2024 (USD Billion)
TABLE 12 Canada monoclonal antibodies market, by indication, 2013 - 2024 (USD Billion)
TABLE 13 Canada monoclonal antibodies market, by end-use, 2013 - 2024 (USD Billion)
TABLE 14 Europe monoclonal antibodies market, by source type, 2013 - 2024 (USD Billion)
TABLE 15 Europe monoclonal antibodies market, by production type, 2013 - 2024 (USD Billion)
TABLE 16 Europe monoclonal antibodies market, by production type, 2013 - 2024 (USD Billion)
TABLE 17 Europe monoclonal antibodies market, by indication, 2013 - 2024 (USD Billion)
TABLE 18 Europe monoclonal antibodies market, by end-use, 2013 - 2024 (USD Billion)
TABLE 19 Germany monoclonal antibodies market, by source type, 2013 - 2024 (USD Billion)
TABLE 20 Germany monoclonal antibodies market, by production type, 2013 - 2024 (USD Billion)
TABLE 21 Germany monoclonal antibodies market, by indication, 2013 - 2024 (USD Billion)
TABLE 22 Germany monoclonal antibodies market, by end-use, 2013 - 2024 (USD Billion)
TABLE 23 UK monoclonal antibodies market, by source type , 2013 - 2024 (USD Billion)
TABLE 24 UK monoclonal antibodies market, by production type, 2013 - 2024 (USD Billion)
TABLE 25 UK monoclonal antibodies market, by indication, 2013 - 2024 (USD Billion)
TABLE 26 UK monoclonal antibodies market, by end-use, 2013 - 2024 (USD Billion)
TABLE 27 Asia Pacific monoclonal antibodies market, by source type, 2013 - 2024 (USD Billion)
TABLE 28 Asia Pacific monoclonal antibodies market, by production type, 2013 - 2024 (USD Billion)
TABLE 29 Asia Pacific monoclonal antibodies market, by indication, 2013 - 2024 (USD Billion)
TABLE 30 Asia Pacific monoclonal antibodies market, by end-use, 2013 - 2024 (USD Billion)
TABLE 31 Japan monoclonal antibodies market, by source type, 2013 - 2024 (USD Billion)
TABLE 32 Japan monoclonal antibodies market, by production type, 2013 - 2024 (USD Billion)
TABLE 33 Japan monoclonal antibodies market, by indication, 2013 - 2024 (USD Billion)
TABLE 34 Japan monoclonal antibodies market, by end-use, 2013 - 2024 (USD Billion)
TABLE 35 China monoclonal antibodies market, by source type, 2013 - 2024 (USD Billion)
TABLE 36 China monoclonal antibodies market, by production type, 2013 - 2024 (USD Billion)
TABLE 37 China monoclonal antibodies market, by indication, 2013 - 2024 (USD Billion)
TABLE 38 China monoclonal antibodies market, by end-use, 2013 - 2024 (USD Billion)
TABLE 39 India monoclonal antibodies market, by source type, 2013 - 2024 (USD Billion)
TABLE 40 India monoclonal antibodies market, by production type, 2013 - 2024 (USD Billion)
TABLE 41 Latin America monoclonal antibodies market, by source type, 2013 - 2024 (USD Billion)
TABLE 42 Latin America monoclonal antibodies market, by production type, 2013 - 2024 (USD Billion)
TABLE 43 Latin America monoclonal antibodies market, by indication, 2013 - 2024 (USD Billion)
TABLE 44 Latin America monoclonal antibodies market, by end-use, 2013 - 2024 (USD Billion)
TABLE 45 Brazil monoclonal antibodies market, by source type, 2013 - 2024 (USD Billion)
TABLE 46 Brazil monoclonal antibodies market, by production type, 2013 - 2024 (USD Billion)
TABLE 47 Brazil monoclonal antibodies market, by indication, 2013 - 2024 (USD Billion)
TABLE 48 Brazil monoclonal antibodies market, by end-use, 2013 - 2024 (USD Billion)
TABLE 49 Mexico monoclonal antibodies market, by source type, 2013 - 2024 (USD Billion)
TABLE 50 Mexico monoclonal antibodies market, by production type, 2013 - 2024 (USD Billion)
TABLE 51 Mexico monoclonal antibodies market, by indication, 2013 - 2024 (USD Billion)
TABLE 52 Mexico Monoclonal antibodies market, by end-use, 2013 - 2024 (USD Billion)
TABLE 53 MEA monoclonal antibodies market, by source type, 2013 - 2024 (USD Billion)
TABLE 54 MEA monoclonal antibodies market, by production type, 2013 - 2024 (USD Billion)
TABLE 55 MEA monoclonal antibodies market, by indication, 2013 - 2024 (USD Billion)
TABLE 56 MEA monoclonal antibodies market, by end-use, 2013 - 2024 (USD Billion)
TABLE 57 South Africa monoclonal antibodies market, by source type, 2013 - 2024 (USD Billion)
TABLE 58 South Africa monoclonal antibodies market, by production type, 2013 - 2024 (USD Billion)
TABLE 59 South Africa monoclonal antibodies market, by indication, 2013 - 2024 (USD Billion)
TABLE 60 South Africa monoclonal antibodies market, by end-use, 2013 - 2024 (USD Billion)